Shrenik Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Shrenik.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Trade Distributors	6.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Should You Be Worried About Shrenik Limited's (NSE:SHRENIK) 1.5% Return On Equity?

Mar 07

Here's Why Shrenik (NSE:SHRENIK) Is Weighed Down By Its Debt Load

Feb 15

Estimating The Intrinsic Value Of Shrenik Limited (NSE:SHRENIK)

Jan 28

Is Shrenik (NSE:SHRENIK) Likely To Turn Things Around?

Jan 11

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Shrenik no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:SHRENIK - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	245	-2,351	N/A	N/A	N/A
6/30/2024	288	-616	N/A	N/A	N/A
3/31/2024	342	-2,355	208	208	N/A
12/31/2023	402	-34	N/A	N/A	N/A
9/30/2023	406	-28	N/A	N/A	N/A
6/30/2023	452	-481	N/A	N/A	N/A
3/31/2023	486	2	468	469	N/A
12/31/2022	482	-11	N/A	N/A	N/A
9/30/2022	461	-28	-94	-94	N/A
6/30/2022	417	-101	N/A	N/A	N/A
3/31/2022	638	-144	-77	-77	N/A
12/31/2021	1,356	-116	N/A	N/A	N/A
9/30/2021	1,721	-117	98	98	N/A
6/30/2021	3,390	-31	N/A	N/A	N/A
3/31/2021	3,637	-15	269	269	N/A
12/31/2020	4,198	11	N/A	N/A	N/A
9/30/2020	5,759	53	231	235	N/A
6/30/2020	6,250	61	N/A	N/A	N/A
3/31/2020	7,956	113	85	104	N/A
12/31/2019	8,771	140	N/A	N/A	N/A
9/30/2019	8,956	134	-369	-301	N/A
6/30/2019	8,683	120	N/A	N/A	N/A
3/31/2019	8,368	111	-247	-181	N/A
12/31/2018	7,743	94	N/A	N/A	N/A
9/30/2018	7,131	93	N/A	N/A	N/A
6/30/2018	6,532	86	N/A	N/A	N/A
3/31/2018	5,932	79	N/A	-469	N/A
3/31/2017	4,277	42	N/A	-131	N/A
3/31/2016	3,292	29	N/A	-75	N/A
3/31/2015	2,657	10	N/A	60	N/A
3/31/2014	2,131	10	N/A	-73	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SHRENIK es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SHRENIK crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SHRENIK crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de SHRENIK crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de SHRENIK crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SHRENIK se prevé que sea elevada dentro de 3 años.

Shrenik Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Chairman & MD recently sold ₹3.6m worth of stock

Chairman & MD recently sold ₹3.4m worth of stock

Chairman & MD recently sold ₹1.9m worth of stock

Chairman & MD recently sold ₹3.1m worth of stock

Second quarter 2025 earnings released

New major risk - Negative shareholders equity

Chairman & MD recently sold ₹1.8m worth of stock

Chairman & MD recently sold ₹244k worth of stock

Chairman & MD recently sold ₹769k worth of stock

Shrenik Limited, Annual General Meeting, Sep 30, 2024

Chairman & MD recently sold ₹313k worth of stock

First quarter 2025 earnings released

Chairman & MD recently sold ₹181k worth of stock

Chairman & MD recently sold ₹728k worth of stock

Insufficient new directors

Shrenik Limited Appoints Nirav Harshvadan Zaveri as Independent Director

Full year 2024 earnings released

Chairman & MD recently sold ₹6.5m worth of stock

Chairman & MD recently sold ₹295k worth of stock

Chairman & MD recently sold ₹1.1m worth of stock

Chairman & MD recently sold ₹542k worth of stock

Chairman & MD recently sold ₹207k worth of stock

Chairman & MD recently sold ₹543k worth of stock

Chairman & MD recently sold ₹544k worth of stock

Third quarter 2024 earnings released

Chairman & MD recently sold ₹626k worth of stock

Chairman & MD recently sold ₹370k worth of stock

Chairman & MD recently sold ₹1.0m worth of stock

Chairman & MD recently sold ₹1.7m worth of stock

Chairman & MD recently sold ₹973k worth of stock

Is Shrenik (NSE:SHRENIK) A Risky Investment?

Chairman & MD recently sold ₹935k worth of stock

First quarter 2024 earnings released: ₹0.77 loss per share (vs ₹0.01 profit in 1Q 2023)

Chairman & MD recently sold ₹1.3m worth of stock

Chairman & MD recently sold ₹1.2m worth of stock

Full year 2023 earnings released: EPS: ₹0.004 (vs ₹0.23 loss in FY 2022)

Chairman & MD recently sold ₹1.1m worth of stock

Is Shrenik (NSE:SHRENIK) Using Debt Sensibly?

Chairman & MD recently sold ₹108k worth of stock

Chairman & MD recently sold ₹2.4m worth of stock

Chairman & MD recently sold ₹2.5m worth of stock

Chairman & MD recently sold ₹1.6m worth of stock

Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.02 loss in 3Q 2022)

Is Shrenik (NSE:SHRENIK) A Risky Investment?

Chairman & MD recently sold ₹425k worth of stock

Chairman & MD recently sold ₹481k worth of stock

Chairman & MD recently sold ₹140k worth of stock

Chairman & MD recently sold ₹805k worth of stock

Second quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.09 loss in 2Q 2022)

Chairman & MD recently sold ₹519k worth of stock

Is Shrenik (NSE:SHRENIK) A Risky Investment?

Shrenik Limited, Annual General Meeting, Sep 29, 2022

Chairman & MD recently sold ₹774k worth of stock

Chairman & MD recently sold ₹957k worth of stock

Chairman & MD recently sold ₹1.2m worth of stock

First quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.06 loss in 1Q 2022)

Chairman & MD recently sold ₹190k worth of stock

Chairman & MD recently sold ₹335k worth of stock

Chairman & MD recently sold ₹233k worth of stock

Be Wary Of Shrenik (NSE:SHRENIK) And Its Returns On Capital

Full year 2022 earnings released: ₹0.23 loss per share (vs ₹0.024 loss in FY 2021)

Investors Could Be Concerned With Shrenik's (NSE:SHRENIK) Returns On Capital

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chairman & MD recently sold ₹12m worth of stock

Shrenik (NSE:SHRENIK) Use Of Debt Could Be Considered Risky

Whole Time Director recently sold ₹9.9m worth of stock

Investors Could Be Concerned With Shrenik's (NSE:SHRENIK) Returns On Capital

Second quarter 2022 earnings released

Chairman & MD recently sold ₹3.6m worth of stock

Insider recently sold ₹782k worth of stock

Board Member recently sold ₹8.5m worth of stock

Does Shrenik (NSE:SHRENIK) Have A Healthy Balance Sheet?

First quarter 2022 earnings released: ₹0.06 loss per share (vs ₹0.03 loss in 1Q 2021)

Independent Director Manali Shah has left the company

Insider recently sold ₹744k worth of stock